EX-23.2 4 d417151dex232.htm EX-23.2 EX-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Acrivon Therapeutics, Inc. of our report dated March 28, 2023, relating to the financial statements, which appears in Acrivon Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

August 11, 2023